Evaluation of the Expression Level of miR-34b in Peripheral Blood for Targeted Treatment Effect and Prognosis in Stage Ⅲb-Ⅳ NSCLC Patients
Objective:To explore the evaluation value of peripheral blood microRNA-34b(miR-34b)for targeted therapy effect and prognosis in patients with stage Ⅲb-Ⅳ non-small cell lung cancer(NSCLC).Methods:A total of 104 NSCLC patients who received targeted treatment from January 2020 to January 2022 were selected.According to the efficacy of targeted treatment,they were divided into the effective group(n= 40)and ineffective group(n=64).All patients were followed up for one year,and based on the prognosis,they were divided into the survival group(n=32)and death group(n=72).Real-time quantitative PCR was used to detect miR-34b in peripheral blood.The receiver operating characteristic curve(ROC)was employed to analyze the evaluation value of peripheral blood miR-34b expression level for the targeted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients.Kaplan-Meier survival curve analysis was used to explore the relationship between different peripheral blood miR-34b expression levels and the prognosis of stage Ⅲb-ⅣNSCLC patients.Results:The peripheral blood miR-34b expression level in the effective group was higher than that in the ineffective group(P<0.05).The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the targeted treatment effect of stage Ⅲb-Ⅳ NSCLC patients was 0.856(P<0.05).The peripheral blood miR-34b expression level in the survival group was higher than that in the death group(P<0.05).The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the prognosis of stage Ⅲb-Ⅳ NSCLC patients was 0.916(P<0.05).The Log-rank test showed a statistically significant difference in survival rate between the miR-34b>2.16 group and miR-34b≤2.16 group(P<0.05).Conclusion:The expression level of peripheral blood miR-34b is associated with the targe-ted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients.Detecting the expression level of peripher-al blood miR-34b is helpful for evaluating the targeted treatment effect and prognosis.
国家科技期刊平台
NSTL
万方数据
维普
